Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Sarcoma 1Pancreatic Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1

Interventions

Gemcitabine 33Cisplatin 28pembrolizumab 19durvalumab 17Oxaliplatin 16Fluorouracil 16Leucovorin 14Magnetic Resonance Spectroscopy 13Specimen Handling 9Biopsy 9lenvatinib 7Nivolumab 7Capecitabine 7Taxes 6Paclitaxel 6Irinotecan 6fludarabine 5Folfox protocol 5Drug Therapy 5Carboplatin 5Albumin-Bound Paclitaxel 5pemigatinib 4Ipilimumab 4Fluorodeoxyglucose F18 4Floxuridine 4Cyclophosphamide 4Bevacizumab 4130-nm albumin-bound paclitaxel 4tremelimumab 3olaparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cholangiocarcinoma × KP 1339 × 1 year × Clear all
NCT04421820 2026-05-18

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

Bold Therapeutics, Inc.

Phase 1/2 Recruiting
220 enrolled
Gastrointestinal

Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡